About

Publications While At HealthPartners

Highlights

selected publications

Journal Article

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. 

Cancer. 2025

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. 

Nature Medicine. 2021

Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. 

Cancer medicine. 2020

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study. 

Journal of Clinical Oncology. 2019

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. 

Lancet Oncology. 2016

Contact

full name

S. S. Ramalingam

Quick Info

Publications

Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.

Collaboration

Co-author network

Map of science